The time between vaccine development and vaccine introduction in the
developing world can be shortened by targeting key decision-makers
with irrefutable evidence of the value of vaccines. IVAC capitalizes on its
experience with the highly successful Pneumococcal Vaccine Accelerated
Development and Introduction Plan (PneumoADIP) and Hib Initiative
projects that were based at JHSPH. Together with rotavirus, also deadly
but vaccine-preventable, all three diseases claim the lives of more than 1.5 million children a year. Vaccines for these diseases have been widely used in rich countries for years, while children in poor countries have gone without. IVAC’s work to strengthen the evidence base for vaccine introduction includes undertaking targeted, policy-focused research in areas such as disease burden, cost-effectiveness, vaccine policy, demand forecasting and disease epidemiology. IVAC projects are made possible with support from institutions, foundations and industry. Our partners also include PATH (path.org), The World Health Organization (who.int), The Centers for Disease Control and Prevention (cdc.gov), The Global Coalition Against Child Pneumonia (worldpneumoniaday.org) and research centers and universities around the globe.
